1-[2-[(5-Cyanopyridin-2-yl)amino]-ethylamino]acetyl-2-(S)-pyrrolidine -carbonitrile: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2002, Pages 2362-2365

  Villhauer, Edwin B ^a   Brinkman, John A ^a   Naderi, Goli B ^a   Dunning, Beth E ^a   Mangold, Bonnie L ^a   Mone, Manisha D ^a   Russell, Mary E ^a   Weldon, Stephen C ^a   Hughes, Thomas E ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [(5 CYANOPYRIDIN 2 YL)AMINO]ETHYLAMINO]ACETYL 2 PYRROLIDINE CARBONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD26; ANTILIPEMIC AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; ENZYME INHIBITORS; GLUCOSE TOLERANCE TEST; HUMANS; MACACA FASCICULARIS; MALE; NITRILES; PROTEASE INHIBITORS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037030602     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025522z     Document Type: Article

References (67)

1. Proline-dependent structural and biological properties of peptides and proteins
2. Catalytic mechanism of dipeptidyl peptidase-IV
3. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
4. Dipeptidyl-peptidase IV-B, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity
5. Cloning and characterization of a novel peptidase from rat and human ileum
6. Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activate human T lymphocytes and modulate immune cell interactions
7. Mouse fibroblast-activation protein-conserved Fap gene oranization and biochemical function as a serine protease
8. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: A candidate target protease, quiescent cell proline dipeptidase
9. Glucagon-like peptide-1 (GLP-1) a newly discovered GI hormone
10. Glucagon-like peptide-1, a new hormone of the enteroinsular axis
11. Glucagon-kike peptides
12. Dipeptidylpeptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36), peptide histidine methionine and is responsible for their degradation in human serum
13. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
14. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV
15. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
16. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV
17. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
18. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
19. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
20. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
21. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
22. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes
23. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in non-insulin dependent diabetes mellitus
24. Near normalizatoin of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM
25. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
26. Biological actions and therapeutic potential of the glucagon-like peptides
27. Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic functions in man
28. Glucagon-like peptide-1 inhibition of gastric-emptying outweighs its insulinotropic effects in healthy humans
29. Is GLP-1 an incretin hormone?
30. The insulinotropic effect of acute exendin-4-administered to humans: Comparison of nondiabetic state to type 2 diabetes
31. Glucagonlike peptide-1 agonist stimulation of β-cell growth and differentiation
32. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice
33. Glucagon-like peptide-1 and exendin-4 improve glucose tolerance and induce islet cell growth in pancreatitis in rats
34. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase
35. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
36. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
37. Glucagon-like peptide-1
38. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models
39. Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic β-cells recorded in vivo
40. Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV; N-phenylphthalimide analogs
41. Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton
42. A potent dipeptide inhibitor of dipeptidyl peptidase IV
43. 1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors
44. Are diprotin A and (Ile-Pro-ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV?
45. Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-Cell activation antigen CD26
46. Mechanism of proline-specific proteinases; (I) substrate specificity of dipeptidyl peptidase IV from pig kidney and prolein-specific endopeptidase from flavobacterium meningosepticum
47. Schneeweiss mechanism and specificity of the substrate cleavage
48. Dipeptidyl Peptidase IV in the Immune System
49. DPP-IV inhibition and therapeutic potential
50. The unique properties of dipeptidyl-peptidase IV (DPP-IV/CD26) and the therapeutic potential of DPP-IV Inhibitors
51. Boronic acid inhibitors of dipeptidyl peptidase IV; a new class of immunosuppressive agents
52. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV
53. Aminoacylpryyolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD26)
54. 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV
55. NVP-DPP728 (1-[[[2-[(5-Cyanopyridin-2-yl)-amino] acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV
56. N-Substituted glycyl 2-cyanopyrrolidines as a new family of DPP-IV inhibitor and their potential use in type 2 diabetes
57. Design and synthesis of N-substituted glycyl 2-cyanopyrrolidines as a new class of DPP-IV inhibitors
58. Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N(substituted)glycine peptoid library
59. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors
60. Dipeptidyl peptidase IV-like molecules: Homologous proteins or homologous activities
61. Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans
62. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes